Organon & Co.: Coronary Artery Disease trials

The registry lists 19 Coronary Artery Disease studies with Organon & Co. as lead sponsor. 0 are open to participants now and 6 have results posted.

Phase 3 10Phase 4 7No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Observational Study of Approaches to Lipid-Lowering Therapy in Russian Patients With Coronary Heart Disease <<Treat to Goal>> (Study P05464)CompletedNCT00730132Results posted
• A Study to Assess the Cholesterol Lowering Effect of Ezetimibe/Simvastatin Combination Tablet Compared to Another Cholesterol Lowering Drug in Elderly Patients With High Cholesterol at High or Moderately High Risk for Coronary Heart Disease (0653A-128)CompletedNCT00535405Phase 3Results posted
• Vytorin (10/20 Or 10/40) Compared to Atorvastatin (10 mg or 20 mg) in Patients With Coronary Artery Disease (0653A-126)(COMPLETED)CompletedNCT00442897Phase 4Results posted
• The Effects of Ezetimibe/Simvastatin 10/20 mg Versus Simvastatin 40 mg in High Cholesterol and Coronary Heart Disease Study (P04039AM2)(COMPLETED)CompletedNCT00423579Phase 4Results posted
• Ezetimibe and Simvastatin in Primary Hypercholesterolemia, Diabetes Mellitus Type 2, and Coronary Heart Disease (COMPLETED)CompletedNCT00423488Phase 3Results posted
• Adding Ezetimibe Tablet to Ongoing Treatment With Atorvastatin in Subjects With High Cholesterol and Multiple Coronary Heart Disease Risk Factors (Study P04060)(COMPLETED)CompletedNCT00319449Phase 4Results posted
• A Long-term Safety and Tolerability Study of Ezetimibe Plus Atorvastatin in Participants With Coronary Heart Disease, Multiple Risk Factors, or Hypercholesterolemia Not Controlled by Atorvastatin (P01418/MK-0653-032)CompletedNCT03882996Phase 3
• A Study of SCH 58235 (Ezetimibe) When Added to Ongoing Therapy With a Statin in Participants With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk Factors (P02173)CompletedNCT03882905Phase 3
• Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)CompletedNCT03867318Phase 3
• Compliance With LDL-Lowering Therapy (Study P05467)(COMPLETED)CompletedNCT00723723
• Switching to Rosuvastatin Versus Adding Ezetimibe to Atorvastatin Versus Doubling the Dose of Atorvastatin in Patients With Hypercholesterolemia and Risk Factors (P03708)TerminatedNCT00651378Phase 4
• Comparison of Co-administration of Ezetimibe Plus Simvastatin Versus Simvastatin Alone in Primary Hypercholesterolemia (P03476)CompletedNCT00651274Phase 4
• Ezetimibe Plus Atorvastatin Versus Atorvastatin in Untreated Subjects With Primary Hypercholesterolemia and Coronary Heart Disease (P03396)CompletedNCT00650689Phase 3
• Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)CompletedNCT00202904Phase 4
• EASEGO Study: Doubling of Atorvastatin/Simvastatin or INEGY in Patients With Hypercholesterolemia and Coronary Artery Disease(CAD)(0653A-089)CompletedNCT00166530Phase 4
• An Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-804)(COMPLETED)CompletedNCT00092638Phase 3
• Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)CompletedNCT00092625Phase 3
• Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-802)(COMPLETED)CompletedNCT00092612Phase 3
• Investigational Drug Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-801)CompletedNCT00092599Phase 3